<DOC>
	<DOCNO>NCT03058809</DOCNO>
	<brief_summary>This study access safety efficacy Viatar™ Oncopheresis System remove meaningful quantity circulate tumor cell blood subject ' breast , colon prostate solid tumor cancer single treatment . CTC reduction measure change circulate tumor cell determine treatment .</brief_summary>
	<brief_title>Evaluation Viatar™ Oncopheresis System Removing CTC From Whole Blood</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>Confirmed diagnosis breast , colon prostate cancer No prior cancer therapy fail first line therapy &gt; = 25 CTC per 7.5 mL blood within 1 week prior oncopheresis treatment &gt; 1 month life expectancy Adequate baseline hematological function assess follow laboratory value : Hemoglobin &gt; 9 g/dl Platelets &gt; 100,000/mm3 WBC &gt; 3,000/mm3 Absolute Neutrophil Count &gt; 1,500/mm3 Coagulation disorder and/or history thromboembolic complication , include know hypersensitivity citrate : e.g. , abnormal platelet count , prothrombin time partial activate thromboplastin time history deep vein thrombus pulmonary embolism Patients know immunodeficiency virus ( HIV )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>